SRNE News and Press, Sorrento Therapeutics Inc. From 03/17/21

SAN DIEGO, March 16, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: CEO Roundtable during WuXi Healthcare Forum 2021 Dr. Henry Ji will participate ...

SORRENTO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE SORRENTO INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Inves...

The Icahn School of Medicine at Mount Sinai has agreed to license to Sorrento Therapeutics (SRNE) antibodies that have neutralizing properties against SARS-CoV-2, the virus that caused COVID-19.Mount Sinai and Sorrento are working on the COVISHIELD program, which is intended to discover combi...

Sorrento is moving forward with the research and development of COVISHIELD antibody combinations with potentially potent neutralizing activities against early COVID-19 pandemic virus isolates as well as current variants of concern. Pre-clinical development of an antibody combination t...

China Oncology Focus Limited, a unit of Lee's Pharmaceutical Holdings announced that it has received regulatory clearance from China’s National Medical Products Administration (“NMPA”) to start a Phase 3 trial for Socazolimab in extensive-stage small-cell lung c...

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm. China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to conduct a Phase III, multicenter, randomized, double blinde...

SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming conference: H.C. WAINWRIGHT Global Life Sciences 2021 (Virtual Co...

Sorrento Therapeutics (SRNE) has received clearance from the FDA for its Investigational New Drug application ((IND)) for its Phase 1 study of the safety and pharmacokinetics of intranasal ((IN)) STI-2099 ((COVIDROPS)) in both healthy volunteers and patients with mild COVID-19.Initial tr...

FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS™) in healthy volunteers and outpatients with mild COVID-19 disease with or without a simultaneous intravenous injection of STI-2020 (COVI-AMG™). I...

The FDA has cleared Sorrento Therapeutics (SRNE) to initiate clinical trail of internally developed anti-CD47 monoclonal antibody, STI-6643.The initial clinical trial will be a basket trial entitled “A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of ...